Angiogenesis inhibitors: current strategies and future prospects

CA Cancer J Clin. Jul-Aug 2010;60(4):222-43. doi: 10.3322/caac.20075. Epub 2010 Jun 16.


Angiogenesis has become an attractive target for drug therapy because of its key role in tumor growth. An extensive array of compounds is currently in preclinical development, with many now entering the clinic and/or achieving approval from the US Food and Drug Administration. Several regulatory and signaling molecules governing angiogenesis are of interest, including growth factors (eg, vascular endothelial growth factor, platelet-derived growth factor, fibroblast growth factor, and epidermal growth factor), receptor tyrosine kinases, and transcription factors such as hypoxia inducible factor, as well as molecules involved in mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) signaling. Pharmacologic agents have been identified that target these pathways, yet for some agents (notably thalidomide), an understanding of the specific mechanisms of antitumor action has proved elusive. The following review describes key molecular mechanisms and novel therapies that are on the horizon for antiangiogenic tumor therapy.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / pharmacology
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use
  • Basic Helix-Loop-Helix Transcription Factors / antagonists & inhibitors
  • Basic Helix-Loop-Helix Transcription Factors / physiology
  • Cell Transformation, Neoplastic
  • Farnesyltranstransferase / antagonists & inhibitors
  • HSP90 Heat-Shock Proteins / antagonists & inhibitors
  • Humans
  • Intracellular Signaling Peptides and Proteins / antagonists & inhibitors
  • Intracellular Signaling Peptides and Proteins / physiology
  • Neoplasms / blood supply
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Neovascularization, Pathologic / prevention & control
  • Nucleic Acid Synthesis Inhibitors / pharmacology
  • Nucleic Acid Synthesis Inhibitors / therapeutic use
  • Protein Binding / drug effects
  • Receptor Protein-Tyrosine Kinases / antagonists & inhibitors
  • Receptor Protein-Tyrosine Kinases / physiology
  • Receptors, Notch / antagonists & inhibitors
  • Receptors, Notch / physiology
  • Signal Transduction / drug effects
  • Thioredoxins / antagonists & inhibitors


  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Basic Helix-Loop-Helix Transcription Factors
  • HSP90 Heat-Shock Proteins
  • Intracellular Signaling Peptides and Proteins
  • Nucleic Acid Synthesis Inhibitors
  • Receptors, Notch
  • Thioredoxins
  • Farnesyltranstransferase
  • Receptor Protein-Tyrosine Kinases